AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer—2026 Update
Cet article présente la mise à jour 2026 des recommandations du "German Gynecological Oncology Group" concernant l'utilisation de biomarqueurs prédictifs ou pronostiques lors de la prise en charge d'un cancer du sein de stade précoce ou avancé
Biomarkers are integral to modern breast cancer management by providing essential information for prognosis and treatment selection. This review presents the 2026 update of the recommendations of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) on therapy-relevant prognostic and predictive biomarkers. The recommendations are based on a structured evaluation of the most recent and clinically relevant evidence using the AGO grading system to support decision-making in routine clinical practice.
The Breast , article en libre accès, 2026